Clinical trial software provider ProofPilot has raised over $12m in a Series B funding round led by Mitsui. The financing round saw participation from Sopris Capital, First Trust Capital Partners, and Excelra among others.

Established in 2014, ProofPilot is a Software as a Service (SaaS) clinical trial research platform.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Making trials inexpensive and simple, the company permits various companies to assess their next-generation healthcare solutions and extend to various groups of subjects.

It provides solutions to the complicated clinical trial market by providing a completely digitised platform with trial process management, self-design study and remote source verification expertise. 

ProofPilot is changing the standard trial model allowing more firms to afford to carry out trials on a broader range of regulated and non-regulated products and services, without needing traditional internal infrastructure. 

This transformation will aid small companies in designing and conducting trials rigorously and substantially boost the research capability of life science firms.

Wellville executive founder Esther Dyson will join the board of directors of ProofPilot as part of the funding. 

ProofPilot’s SaaS product allows users to create, launch, participate and engage in research studies. 

ProofPilot CEO and co-founder Matthew Amsden said: “Through our cost-effective and digitally-enabled platform, pharmaceutical and medical device companies can expand the efficacies of their existing products and explore the potential of digital health solutions. 

“For the first time, health & wellness companies can now access clinical trials to substantiate their products and services at a manageable cost. 

“Moreover, participants can seamlessly engage in clinical trial support.”